Edition:
United Kingdom

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

1,293JPY
24 May 2019
Change (% chg)

¥8 (+0.62%)
Prev Close
¥1,285
Open
¥1,280
Day's High
¥1,293
Day's Low
¥1,267
Volume
831,200
Avg. Vol
1,069,986
52-wk High
¥2,208
52-wk Low
¥1,226

Latest Key Developments (Source: Significant Developments)

Mitsubishi Tanabe Pharma Corp - To Transfer Shares In Unit Tanabe Seiyaku Yoshiki Factory To Nipro Pharma
Monday, 4 Feb 2019 

Mitsubishi Tanabe Pharma Corp <4508.T>::MITSUBISHI TANABE PHARMA CORP - TO TRANSFER SHARES IN UNIT TANABE SEIYAKU YOSHIKI FACTORY TO NIPRO PHARMA.  Full Article

Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .  Full Article

Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018.  Full Article

Mitsubishi Tanabe Pharma completes purchase of NeuroDerm
Wednesday, 18 Oct 2017 

Oct 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it completed purchase of NeuroDerm Ltd <<>>.Purchase plan was announced on July 24.  Full Article

Mitsubishi Tanabe Pharma sells drug sales unit
Monday, 2 Oct 2017 

Oct 2(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it sold 100 percent stake in a drug sales unit to Nipro, on Oct. 1.Previous plan was announced on March 28.  Full Article

‍Mitsubishi Tanabe Pharma America says signs agreement with Option Care for national home infusion services​
Wednesday, 6 Sep 2017 

Sept 6 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:‍Mitsubishi Tanabe Pharma America says signs agreement with Option Care for national home infusion services​.‍Mitsubishi Tanabe Pharma America says agreement with Option Care Enterprises to become a national provider of home infusion services for Radicava​.  Full Article

Neuroderm calls shareholders meeting to approve Mitsubishi Tanabe acquisition
Tuesday, 1 Aug 2017 

Aug 1 (Reuters) - Neuroderm Ltd :Neuroderm announces extraordinary general meeting of shareholders to approve acquisition by Mitsubishi Tanabe Pharma Corporation.  Full Article

Mitsubishi Chemical Holdings consolidated subsidiary to buy NeuroDerm for about $1.1 bln
Monday, 24 Jul 2017 

July 24(Reuters) - Mitsubishi Chemical Holdings Corp <4188.T>:Says its consolidated subsidiary Mitsubishi Tanabe Pharma Corp <<<4508.T>>> will buy NeuroDerm Ltd <<>>, for about $1.1 billion (about 124.1 billion yen), $39 per share, effective October .  Full Article

Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma for $1.1 bln
Monday, 24 Jul 2017 

July 24 (Reuters) - Neuroderm Ltd :Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma corporation for US$1.1 billion in cash.Mitsubishi Tanabe Pharma will acquire neuroderm for us$39 per share in cash.Neuroderm Ltd says currently anticipates transaction will close in Q4 of 2017.Neuroderm deal has received unanimous approval by board and implies an equity value of approximately us$1.1 billion.Special meeting of shareholders to approve transaction is expected to be held this fall.  Full Article

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I
Monday, 12 Jun 2017 

June 12 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Says rating outlook stable -R&I.  Full Article

Nikkei turns up, marks 4th day of gains on U.S.-China trade hopes

TOKYO, Feb 21 Japan's Nikkei reversed course and ended higher as optimism over U.S.- China trade talks lifted companies which have large exposure to China such as Yaskawa Electric and Fanuc.